2022 Fiscal Year Final Research Report
New therapy method to inhibit cancer metastasis-initiating cell targeting ZIP10
| Project/Area Number |
19H03149
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 42040:Laboratory animal science-related
|
|---|
| Research Institution | Aichi Gakuin University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
三原 圭一朗 藤田医科大学, 国際再生医療センター, 教授 (90363077)
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | 癌転移 |
|---|
| Outline of Final Research Achievements |
The concept of metastasis-initiating cells (MICs) has been proposed. MICs originate in the primary tumors and are considered special cells to promote cancer metastasis. However, MICs have not been investigated in detail. We successfully isolated MICs from primary cancer tissues of a scirrhous gastric cancer patient, and then knocked out ZIP10 expression via genome editing methods. The ZIP10-deficient MICs showed the decreased proliferation, colony formation activity, and invasion activity compared with the wild-type MICs. ZIP10 is a novel target to inhibit cancer metastasis.
|
| Free Research Field |
腫瘍生物学
|
| Academic Significance and Societal Importance of the Research Achievements |
癌転移研究は大変遅れている。その理由に、癌転移の良いモデルがない現状がある。我々は、癌転移でメインプレーヤーとなる癌転移開始細胞（MIC）を、スキルス胃癌患者から成功裡に単離した。その解析から、ZIP10がMICの機能維持に重要で、癌転移抑制に有用な新規標的であることが分かった。癌の死因の大半は癌転移による。故に癌患者の予後において、癌転移抑止医療が大切になる。本成果は、癌転移抑止医療の実現に繋がる社会的意義を有する。
|
